Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

139

Enrollment

INDUSTRY

Sponsor class

Stopped Early Termination for Reasons other than Safety

Conditions

Inflammatory Bowel Disease

Interventions

DRUG: Filgotinib
DRUG: Placebo
DRUG: Standard of Care

Sponsor

Lakefront Biotherapeutics NV

Collaborators

[object Object]